

# **EHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias**

## **Abstract / clinical case submission & travel grant guidelines**

### **Introduction**

The abstract / clinical case submission & travel grant guidelines of the EHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias are intended to provide clear instructions before submitting an abstract / a clinical case or travel grant application. **You are kindly requested to carefully read the guidelines stated below.**

The EHA and the Scientific Program Committee (SPC) of the meeting maintain the right to reject any abstract and clinical case submission / travel grant application that does not meet the requirements below.

### **Table of Contents**

Key Dates .....	2
Abstract and clinical case submission.....	2
1. Terms and conditions .....	2
2. Applicable law and jurisdiction.....	3
3. Submission guidelines.....	3
4. Topics.....	3
5. Submission specifications.....	4
6. Review, selection and publication.....	4
Travel grant application.....	4
1. Eligibility criteria.....	4
2. Application Process.....	5
3. Selection .....	5
4. Travel grant coverage.....	5
5. Obligation of grant recipients.....	5
6. Deadline .....	5
7. Notification.....	5

## Key Dates

Date	Item
October 15, 2024	Abstract submission & travel grant application open
February 10, 2025 (23:59 CET)	Abstract submission & travel grant application deadline
February 20, 2025	Notification to abstract submitters & travel grant recipients
March 7, 2025 (23:59 CET)	Abstract & travel grant withdraw deadline

## Abstract and clinical case submission

### 1. Terms and conditions

- 1) The Scientific Program Committee (SPC) encourages the submission of original scientific material unpublished at the time of the abstract/clinical submission deadline:
  - I. Abstracts/clinical cases submitted to regional or national hematology meetings can be submitted to the Scientific Meeting for inclusion in the program;
  - II. Abstracts/clinical cases submitted to large international meetings which are organized in the same period as the EHA Scientific Meeting (March – May 2025) are allowed to be submitted to the meeting.
  - III. Abstracts/clinical cases submitted to other large international meetings may also be submitted providing a clear indication about significant novel or updated information included in the appropriate abstract/clinical case submission field.
- 2) Authors of submitted abstracts shall be the sole and exclusive owner of the abstract and all associated intellectual property rights. By submitting the abstract to EHA, the author grants EHA the right to use and (commercial) reprint the abstract in relation to the Scientific Meeting. Authors of submitted abstracts understand and agree that EHA will not pay compensation for this license.
- 3) Authors of submitted abstracts guarantee that the abstract (and all associated intellectual property rights) is free of any third-party rights to the fullest extent permitted by law, including but not limited to, inventor's rights of remuneration and any other ancillary rights.
- 4) By submitting an abstract, the submitting author confirms that they have approval from all the co-authors to submit and use the data in the abstract.
- 5) Submitted abstracts are considered embargoed from the time of submission. The embargo is lifted at the start of the meeting

- 6) Please do not submit the same study in multiple abstracts/clinical cases. Abstracts/clinical cases that appear as more than one version of a single study will be rejected.
- 7) Similarly, abstracts/clinical cases or (close) copies, may not be submitted under more than 1 (one) topic.

## 2. Applicable law and jurisdiction

The above Terms and conditions are governed by the laws of the Netherlands. Any dispute related to these terms and conditions and the use or publication of the abstract shall be exclusively submitted to the district court in the Hague, the Netherlands.

## 3. Submission guidelines

The submitted abstracts or clinical cases should fully adhere to the guidelines below.

- 1) Abstracts or clinical cases should be submitted in clear (American) English to allow the reviewers to focus on the scientific content of the abstract/clinical case. Non-English-speaking authors are encouraged to have their abstract/clinical case checked for grammar and spelling.
- 2) The SPC assumes all presenting authors have proficiency in English, thus are able to present and respond to questions.
- 3) In clinical studies, please state whether informed consent was obtained.
- 4) The title and text may not contain trade names.
- 5) If off label use of drugs was involved, please state this clearly.
- 6) Withdrawal policy: If authors wish to withdraw their abstracts/clinical cases from presentation or publication, they are requested to confirm with the EHA Executive Office via the confirmation form (provided in the notification letter) before **March 7, 2025 (23:59 CET)**. Consequently, the abstract/clinical case will not be presented nor published.

## 4. Topics

Please select the most appropriate topic during the abstract/clinical case submission:

- 1) Germ-line and acquired predisposition to sAML
- 2) Clonal progression from other myeloid diseases (BM-failure s., MDS, MPN)
- 3) sAML development as a result of cancer treatment (after chemotherapy, CAR-T, gene therapy)
- 4) Genetic characteristics of sAML
- 5) Treatment of sAML

- 6) Allogeneic stem cell transplantation (donor-derived sAML)

## 5. Submission specifications

- 1) Title count: max. 300 characters incl. space.
- 2) Character limit: 3500 characters (incl. spaces & punctuation and headers in the template).
- 3) Please use the following subheadings: Background / Aims / Methods / Results / Summary - Conclusion
- 4) Images have to be submitted as JPEG, tif, or gif files:
  - I. Due to limited space, only a simple graph/image can be submitted.
  - II. Images and graphs should reproduce well in black and white.
  - III. Image file should not exceed 500KB.
- 5) Authors: There is no limit to the number of authors.
- 6) References are obligatory when submitting an abstract or clinical case.

## 6. Review, selection and publication

- 1) All submitted abstracts/clinical cases will be reviewed by the Scientific Program Committee of the EHA-SWG Scientific Meeting.
- 2) Abstracts/clinical cases may be selected for
  - oral presentation
  - poster presentation
  - rejection
- 3) Only the submitting author will receive a notification letter of acceptance for oral presentation, poster presentation, or a notice of rejection, by email by **February 20, 2025**.
- 4) Authors of abstracts selected for an oral presentation or a poster presentation will be informed about the date of the session, and presentation guidelines will be provided.
- 5) Oral and poster abstract presenters will need to register themselves in order to present their abstracts in the Scientific Meeting.

## Travel grant application

### 1. Eligibility criteria

- 1) The applicant is 36 years of age or younger at the time of travel grant application.
- 2) The applicant is an EHA member or has applied for a Junior membership by **February 10, 2025**.
- 3) The membership fee has been paid by **February 19, 2025**.



- 4) The applicant is the first, presenting and submitting author of an accepted abstract.

## 2. Application Process

- 1) Interested individuals can indicate that you wish to apply for a travel grant in the abstract submission form and provide all the necessary details on the form.
- 2) The travel grant applicant will be asked to confirm your eligibility as per the above if necessary.

## 3. Selection

- 1) The applications will be reviewed by the meeting chairs.
- 2) Only applications that meet the eligibility criteria will be considered.
- 3) The selection of travel grant recipients will be based on the abstract score, and will be at the meeting chairs' discretion.
- 4) The number of available travel grants is limited to 10.

## 4. Travel grant coverage

- 1) Complimentary registration arranged by EHA for on-site attendance.
- 2) Maximum of €500 compensation for travel arrangements. A reimbursement form must be filled out, and the grant amount will be transferred after the meeting based on attendance.

## 5. Obligation of grant recipients

- 1) Grant recipients must confirm their acceptance by **March 7, 2025**, and provide any necessary documentation to facilitate the arrangements.
- 2) Grant recipients must attend the full scientific meeting (sign-in will be required at the beginning of each day).

## 6. Deadline

The deadline for travel grant applications is **February 10, 2025 (23:59 CET)**.

## 7. Notification

Applicants will be notified of their travel grant status by **February 20, 2025**.